You are here

shingles

GSK signs shingles vaccine deal with China's Zhifei for around $3 bln

GSK signs shingles vaccine deal with China's Zhifei for around $3 bln

Reuters

Chongqing Zhifei Biological

Flag link:

In GSK's trial of shingles vaccine in China, Shingrix keeps it 100

In GSK's trial of shingles vaccine in China, Shingrix keeps it 100

Fierce Pharma

Flag link:

Pfizer begins plan to challenge Shingrix with an mRNA vaccine

Pfizer begins plan to challenge Shingrix with an mRNA vaccine

BioPharma Dive

Flag link:

Curevo Vaccine announces closing of $26m Series A1 round

Curevo Vaccine announces closing of $26m Series A1 round

Pharmaceutical Business Review

Flag link:

GSK’s Shingrix showed to offer ten years of shingles protection in study

GSK’s Shingrix showed to offer ten years of shingles protection in study

Clinical Trials Arena

clinical trials

Flag link:

The never-ending Zostavax story – in court. Merck gets a win, but thousands more lawsuits pending

The never-ending Zostavax story – in court. Merck gets a win, but thousands more lawsuits pending

Endpoints

Flag link:

Moderna to develop mRNA-based shingles vaccine

Moderna to develop mRNA-based shingles vaccine

Yahoo/Reuters

Moderna Therapeutics

Flag link:

Vaccines upstart Curevo has designs on blockbuster GSK franchise

Vaccines upstart Curevo has designs on blockbuster GSK franchise

Pharmaforum

Flag link:

Pfizer, BioNTech to develop shingles shot, after COVID-19 vaccine success

Pfizer, BioNTech to develop shingles shot, after COVID-19 vaccine success

Reuters

Flag link:

As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine's reach

As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine's reach

Fierce Pharma

Flag link:

GlaxoSmithKline plans to 'relaunch' Shingrix after the pandemic decimated sales

GlaxoSmithKline plans to 'relaunch' Shingrix after the pandemic decimated sales

Fierce Pharma

Flag link:

FDA adds Guillain-Barré syndrome warning to GlaxoSmithKline’s shingles vaccine

FDA adds Guillain-Barré syndrome warning to GlaxoSmithKline’s shingles vaccine

Endpoints

Guillain-Barré Syndrome

Flag link:

GSK's Shingrix supply recovers thanks to drop in vaccinations, uninterrupted production

GSK's Shingrix supply recovers thanks to drop in vaccinations, uninterrupted production

Fierce Pharma

Flag link:

JPM: Glaxo sees enormous Shingrix potential, but a supply gap still stands in the way

JPM: Glaxo sees enormous Shingrix potential, but a supply gap still stands in the way

Fierce Pharma

Flag link:

GlaxoSmithKline's Shingrix supply will vault upward, CEO says—in 2024, that is

GlaxoSmithKline's Shingrix supply will vault upward, CEO says—in 2024, that is

Fierce Pharma

Flag link:

GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle China

GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle China

Fierce Pharma

Flag link:

Sales of shingles vaccine boost profits at GSK

Sales of shingles vaccine boost profits at GSK

Yahoo/Reuters

Flag link:

GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'

GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'

Fierce Pharma

Flag link:

Senators demand more from GlaxoSmithKline to boost Shingrix supply

Senators demand more from GlaxoSmithKline to boost Shingrix supply

Fierce Pharma

Flag link:

GlaxoSmithKline limits Shingrix orders, delays TV commercials amid 'unprecedented' demand

GlaxoSmithKline limits Shingrix orders, delays TV commercials amid 'unprecedented' demand

Fierce Pharma

Flag link:

Pages